羟苯磺酸钙对糖尿病肾病患者微炎症状态的影响分析
|
摘要
目的探讨羟苯磺酸钙对糖尿病肾病患者微炎症状态的影响。方法选取2017年4月～2018年4月期间我院糖尿病肾病100例患者(实施奇偶数分组模式),对照组的50例患者进行骨化三醇治疗,观察组的50例患者进行羟苯磺酸钙治疗,随后对比两组患者的IL-6、PCT、hs-CRP、总有效率、ALB、PA、Hb、TP/24h、Scr、TNF-α。结果观察组ALB(30.12±4.39)g/L、PA(0.13±0.05)g/L、Hb(121.33±10.42)g/L、TP/24h(1.95±0.74)g、Scr(80.33±4.19)μmol/L、TNF-α(31.19±3.21)ng/L、IL-6(15.84±2.15)ng/L、PCT(1.86±0.55)μg/L、hs-CRP(2.31±0.05)mg/L、总有效率(98.00%)均优于对照组(P <0.05)。结论对糖尿病肾病患者实施羟苯磺酸钙治疗效果显著,可改善微炎症状态。
Objective To explore the effect of Calcium Dobesilate on microinflammation in patients with diabetic nephropathy. Methods 100 patients with diabetic nephropathy in our hospital from April 2017 to April 2018 were divided into groups in odd and even grouping mode. 50 patients in the control group were treated with calcitriol.Another 50 patients in the observation group were treated with Calcium Dobesilate treatment. IL-6, PCT, hs-CRP, total effective rate, ALB, PA, Hb, TP/24 h, Scr, TNF-α between the two groups were compared. Results ALB(30.12±4.39) g/L, PA(0.13±0.05) g/L, Hb(121.33±10.42) g/L, TP/24 h(1.95±0.74) g, Scr(80.33±4.19) Umol/L, TNF-α(31.19±3.21) ng/L, IL-6(15.84±2.15) ng/L, PCT(1.86±0.55) ug/L, hs-CRP(2.31±0.05) mg/L, total effective rate(98.00%) in the observation group were better than that in the control group(P < 0.05). Conclusion The treatment of Calcium Dobesilate in patients with diabetic nephropathy is effective and can improve the microinflammation state.
Objective To explore the effect of Calcium Dobesilate on microinflammation in patients with diabetic nephropathy. Methods 100 patients with diabetic nephropathy in our hospital from April 2017 to April 2018 were divided into groups in odd and even grouping mode. 50 patients in the control group were treated with calcitriol.Another 50 patients in the observation group were treated with Calcium Dobesilate treatment. IL-6, PCT, hs-CRP, total effective rate, ALB, PA, Hb, TP/24 h, Scr, TNF-α between the two groups were compared. Results ALB(30.12±4.39) g/L, PA(0.13±0.05) g/L, Hb(121.33±10.42) g/L, TP/24 h(1.95±0.74) g, Scr(80.33±4.19) Umol/L, TNF-α(31.19±3.21) ng/L, IL-6(15.84±2.15) ng/L, PCT(1.86±0.55) ug/L, hs-CRP(2.31±0.05) mg/L, total effective rate(98.00%) in the observation group were better than that in the control group(P < 0.05). Conclusion The treatment of Calcium Dobesilate in patients with diabetic nephropathy is effective and can improve the microinflammation state.
引文
[1]张明霞,刘珊,谭德敏,等.羟苯磺酸钙联合福辛普利治疗临床期糖尿病肾病的疗效[J].中国老年学杂志,2013,33(4):927-928.
[2]唐光钰,唐今尧.糖肾康煎剂与羟苯磺酸钙联合黄芪疏血通治疗糖尿病肾病IV期48例的临床观察[J].世界中医药,2014,14(9):1165-1167,1171.
[3]Cai,G.,Zheng,Y.,Sun,X.,et al.Prevalence, awareness,treatment, and control of hypertension in elderly adults with chronic kidney disease:Results from the survey of prevalence, awareness, and treatment rates in chronic kidney disease patients with hypertension in china[J].Journal of the American Geriatrics Society,2013,61(12):2160-2167.
[4]崔向勇.观察羟苯磺酸钙胶囊联合复方丹参滴丸治疗糖尿病性视网膜病变及肾病的疗效[J].糖尿病新世界,2016,34(4):31-32.
[5]王新华,熊重祥,路建饶,等.羟苯磺酸钙胶囊联合肾炎康复片治疗糖尿病肾病的临床效果观察[J].中国综合临床,2013,29(11):1191-1194.
[6]曹翠平,于婉,马小羽,等.羟苯磺酸钙和缬沙坦联合治疗对老年早期糖尿病肾病患者ET和CysC的影响[J].实用药物与临床,2014,25(6):677-680.
[7]高震,张迎春.替米沙坦联合羟苯磺酸钙治疗老年糖尿病肾病合并高血压的临床效果[J].中国医药导报,2015,14(24):136-138,145.
[8]王平,万世文,杜新芝,等.羟苯磺酸钙分散片联合α-硫辛酸治疗糖尿病肾病Ⅳ期的临床研究[J].中国中西医结合肾病杂志,2015,16(10):898-900.
[9]李泉清,王华.羟苯磺酸钙联合黄葵胶囊治疗老年早期糖尿病肾病蛋白尿的疗效[J].中国老年学杂志,2016,14(4):834-836.
[10]庹艳红,郑卫华,马特安.羟苯磺酸钙对维持性腹膜透析患者微炎症状态的影响[J].医学研究杂志, 2014,43(6):147-149.
[11]LambersHeerspink,H.J.,Weldegiorgis,M.,Inker,L.A.,et al.Estimated GFR decline as a surrogate end point for kidney failure:A post hoc analysis from the reduction of end points in non-insulin-dependent diabetes with the Angiotensin II Antagonist Losartan(RENAAL)study and Irbesartan Diabetic Nephropathy Trial(IDNT)[J].American Journal of Kidney Diseases:The official journal of the National Kidney Foundation,2014,63(2):244-250.
[12]马盼,庞雪峰.厄贝沙坦联合羟苯磺酸钙对早期2型糖尿病合并高血压患者肾内血流动力学的影响[J].海南医学,2018,29(8):1055-1059.
[13]侯荣.丹红注射液联合羟苯磺酸钙治疗糖尿病肾病临床观察[J].现代中西医结合杂志,2016,22(8):853-855.
[14]余后意,熊小波,江世亭,等.羟苯磺酸钙胶囊联合肾炎康复片治疗糖尿病肾病的临床疗效观察[J].当代医学,2014,15(33):155-156.
[15]刘翠兰,刘华,程锦绣,等.骨化三醇联合羟苯磺酸钙对糖尿病腹膜透析患者微炎症及营养状态的影响[J].中国临床医生杂志,2017,45(3):67-70.
[16]Boertien,W.E.,Meijer,E.,Li,J, et al.Relationship of copeptin, a surrogate marker for arginine vasopressin,with change in total kidney volume and gfr decline in autosomal dominant polycystic kidney disease:Results from the crisp cohort[J].American Journal of Kidney Diseases:The official journal of the National Kidney Foundation,2013,61(3):420-429.
[17]王蕊,安建立,朱悦雨,等.不同剂量前列地尔辅助羟苯磺酸钙对糖尿病肾病患者肾脏功能、炎性细胞因子及氧化应激水平的影响[J].国际老年医学杂志,2017,38(5):211-214.
[18]刘晓晖,曾彩红.羟苯磺酸钙联合厄贝沙坦治疗临床蛋白尿期糖尿病肾病的疗效观察[J].实用临床医药杂志,2014,18(1):69-71,85.
[2]唐光钰,唐今尧.糖肾康煎剂与羟苯磺酸钙联合黄芪疏血通治疗糖尿病肾病IV期48例的临床观察[J].世界中医药,2014,14(9):1165-1167,1171.
[3]Cai,G.,Zheng,Y.,Sun,X.,et al.Prevalence, awareness,treatment, and control of hypertension in elderly adults with chronic kidney disease:Results from the survey of prevalence, awareness, and treatment rates in chronic kidney disease patients with hypertension in china[J].Journal of the American Geriatrics Society,2013,61(12):2160-2167.
[4]崔向勇.观察羟苯磺酸钙胶囊联合复方丹参滴丸治疗糖尿病性视网膜病变及肾病的疗效[J].糖尿病新世界,2016,34(4):31-32.
[5]王新华,熊重祥,路建饶,等.羟苯磺酸钙胶囊联合肾炎康复片治疗糖尿病肾病的临床效果观察[J].中国综合临床,2013,29(11):1191-1194.
[6]曹翠平,于婉,马小羽,等.羟苯磺酸钙和缬沙坦联合治疗对老年早期糖尿病肾病患者ET和CysC的影响[J].实用药物与临床,2014,25(6):677-680.
[7]高震,张迎春.替米沙坦联合羟苯磺酸钙治疗老年糖尿病肾病合并高血压的临床效果[J].中国医药导报,2015,14(24):136-138,145.
[8]王平,万世文,杜新芝,等.羟苯磺酸钙分散片联合α-硫辛酸治疗糖尿病肾病Ⅳ期的临床研究[J].中国中西医结合肾病杂志,2015,16(10):898-900.
[9]李泉清,王华.羟苯磺酸钙联合黄葵胶囊治疗老年早期糖尿病肾病蛋白尿的疗效[J].中国老年学杂志,2016,14(4):834-836.
[10]庹艳红,郑卫华,马特安.羟苯磺酸钙对维持性腹膜透析患者微炎症状态的影响[J].医学研究杂志, 2014,43(6):147-149.
[11]LambersHeerspink,H.J.,Weldegiorgis,M.,Inker,L.A.,et al.Estimated GFR decline as a surrogate end point for kidney failure:A post hoc analysis from the reduction of end points in non-insulin-dependent diabetes with the Angiotensin II Antagonist Losartan(RENAAL)study and Irbesartan Diabetic Nephropathy Trial(IDNT)[J].American Journal of Kidney Diseases:The official journal of the National Kidney Foundation,2014,63(2):244-250.
[12]马盼,庞雪峰.厄贝沙坦联合羟苯磺酸钙对早期2型糖尿病合并高血压患者肾内血流动力学的影响[J].海南医学,2018,29(8):1055-1059.
[13]侯荣.丹红注射液联合羟苯磺酸钙治疗糖尿病肾病临床观察[J].现代中西医结合杂志,2016,22(8):853-855.
[14]余后意,熊小波,江世亭,等.羟苯磺酸钙胶囊联合肾炎康复片治疗糖尿病肾病的临床疗效观察[J].当代医学,2014,15(33):155-156.
[15]刘翠兰,刘华,程锦绣,等.骨化三醇联合羟苯磺酸钙对糖尿病腹膜透析患者微炎症及营养状态的影响[J].中国临床医生杂志,2017,45(3):67-70.
[16]Boertien,W.E.,Meijer,E.,Li,J, et al.Relationship of copeptin, a surrogate marker for arginine vasopressin,with change in total kidney volume and gfr decline in autosomal dominant polycystic kidney disease:Results from the crisp cohort[J].American Journal of Kidney Diseases:The official journal of the National Kidney Foundation,2013,61(3):420-429.
[17]王蕊,安建立,朱悦雨,等.不同剂量前列地尔辅助羟苯磺酸钙对糖尿病肾病患者肾脏功能、炎性细胞因子及氧化应激水平的影响[J].国际老年医学杂志,2017,38(5):211-214.
[18]刘晓晖,曾彩红.羟苯磺酸钙联合厄贝沙坦治疗临床蛋白尿期糖尿病肾病的疗效观察[J].实用临床医药杂志,2014,18(1):69-71,85.